Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Pipeline Drugs Market Report Overview

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas that originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include a lump or swelling in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles, and dizziness or loss of balance. Treatment includes surgery, radiotherapy, and chemotherapy.

The Peripheral Nerve Sheath Tumors drugs in development market research report provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Nerve Sheath Tumors and features dormant and discontinued projects.

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Segmentation by Targets

Some of the targets in the Peripheral Nerve Sheath Tumors pipeline are Programmed Cell Death Protein 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, and Mast/Stem Cell Growth Factor Receptor Kit among others. Programmed Cell Death Protein 1 was the largest target in the pipeline.

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Targets

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Targetsmore Peripheral Nerve Sheath Tumors pipeline drugs market target insights, download a free report sample

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the mechanisms of action in the Peripheral Nerve Sheath Tumors pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor among others. Programmed Cell Death Protein 1 Antagonist was the leading MoA in the pipeline.

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Mechanisms of Action

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more MoA insights into the Peripheral Nerve Sheath Tumors pipeline drugs market, download a free report sample

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Peripheral Nerve Sheath Tumors pipeline drugs market are intravenous, oral, intraperitoneal, and intrapleural among others. The majority of the pipeline drugs followed the oral route of administration.

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Routes of Administration

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Routes of AdministrationFor more routes of administration insights into the Peripheral Nerve Sheath Tumors pipeline drugs market, download a free report sample

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Segmentation by Molecule Types

The leading molecule types in the Peripheral Nerve Sheath Tumors pipeline drugs market are small molecule, monoclonal antibody, and oncolytic virus among others. Small molecule was the leading molecule type in the pipeline.

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Molecule Types

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule type insights into the Peripheral Nerve Sheath Tumors pipeline drugs market, download a free report sample

Peripheral Nerve Sheath Tumors Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Peripheral Nerve Sheath Tumors pipeline drugs market are Bristol-Myers Squibb Co, Calithera Biosciences Inc, Epizyme Inc, and Mirati Therapeutics Inc among others.

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis by Key Companies

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Analysis by Key CompaniesTo know more about the Peripheral Nerve Sheath Tumors pipeline drugs market companies, download a free report sample

Peripheral Nerve Sheath Tumors Pipeline Drugs Market Report Overview

Key Targets Programmed Cell Death Protein 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, and Mast/Stem Cell Growth Factor Receptor Kit
Key Mechanism of Actions Programmed Cell Death Protein 1 Antagonist, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor
Key Routes of Administration Intravenous, Oral, Intraperitoneal, and Intrapleural
Key Molecule Types Small Molecule, Monoclonal Antibody, and Oncolytic Virus
Key Companies Bristol-Myers Squibb Co, Calithera Biosciences Inc, Epizyme Inc, and Mirati Therapeutics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).

  • The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

3SBio Inc
Adaptimmune Therapeutics Plc
Advenchen Laboratories LLC
Aldeyra Therapeutics Inc
Apexian Pharmaceuticals Inc
Ascentage Pharma Group International
AstraZeneca Plc
BeiGene Ltd
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Eisai Co Ltd
Epizyme Inc
F. Hoffmann-La Roche Ltd
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Merck & Co Inc
Mirati Therapeutics Inc
Moleculin Biotech Inc
Novartis AG
Oncomatryx Biopharma SL
Open Therapeutics LLC
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Shenzhen Chipscreen Biosciences Co Ltd
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
Tango Therapeutics Inc
Vyriad Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Overview

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Companies Involved in Therapeutics Development

3SBio Inc

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

Aldeyra Therapeutics Inc

Apexian Pharmaceuticals Inc

Ascentage Pharma Group International

AstraZeneca Plc

BeiGene Ltd

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Eisai Co Ltd

Epizyme Inc

F. Hoffmann-La Roche Ltd

Jiangsu Hengrui Medicine Co Ltd

Karyopharm Therapeutics Inc

Merck & Co Inc

Mirati Therapeutics Inc

Moleculin Biotech Inc

Novartis AG

Oncomatryx Biopharma SL

Open Therapeutics LLC

Otsuka Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Shenzhen Chipscreen Biosciences Co Ltd

Sino Biopharmaceutical Ltd

Sorrento Therapeutics Inc

Tango Therapeutics Inc

Vyriad Inc

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Drug Profiles

(cedazuridine + decitabine) – Drug Profile

Product Description

Mechanism Of Action

afamitresgene autoleucel – Drug Profile

Product Description

Mechanism Of Action

AL-2846 – Drug Profile

Product Description

Mechanism Of Action

Annamycin – Drug Profile

Product Description

Mechanism Of Action

APG-115 – Drug Profile

Product Description

Mechanism Of Action

APX-3330 – Drug Profile

Product Description

Mechanism Of Action

axitinib – Drug Profile

Product Description

Mechanism Of Action

camrelizumab – Drug Profile

Product Description

Mechanism Of Action

cobimetinib fumarate – Drug Profile

Product Description

Mechanism Of Action

CS-2164 – Drug Profile

Product Description

Mechanism Of Action

ecubectedin – Drug Profile

Product Description

Mechanism Of Action

eribulin mesylate – Drug Profile

Product Description

Mechanism Of Action

everolimus – Drug Profile

Product Description

Mechanism Of Action

ganetespib – Drug Profile

Product Description

Mechanism Of Action

HSV-1716 – Drug Profile

Product Description

Mechanism Of Action

ipilimumab – Drug Profile

Product Description

Mechanism Of Action

ipilimumab + nivolumab – Drug Profile

Product Description

Mechanism Of Action

MRTX-9768 – Drug Profile

Product Description

Mechanism Of Action

OMTX-703 – Drug Profile

Product Description

Mechanism Of Action

Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor – Drug Profile

Product Description

Mechanism Of Action

Oncolytic Virus to Target CD46 and SLC5A5 for Oncology – Drug Profile

Product Description

Mechanism Of Action

pamiparib – Drug Profile

Product Description

Mechanism Of Action

pembrolizumab – Drug Profile

Product Description

Mechanism Of Action

pexidartinib hydrochloride – Drug Profile

Product Description

Mechanism Of Action

sapanisertib – Drug Profile

Product Description

Mechanism Of Action

selinexor – Drug Profile

Product Description

Mechanism Of Action

selumetinib sulfate – Drug Profile

Product Description

Mechanism Of Action

sitravatinib malate – Drug Profile

Product Description

Mechanism Of Action

SSGJ-609A – Drug Profile

Product Description

Mechanism Of Action

tazemetostat hydrobromide – Drug Profile

Product Description

Mechanism Of Action

telaglenastat hydrochloride – Drug Profile

Product Description

Mechanism Of Action

TNG-908 – Drug Profile

Product Description

Mechanism Of Action

TQB-3234 – Drug Profile

Product Description

Mechanism Of Action

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Dormant Projects

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by 3SBio Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Adaptimmune Therapeutics Plc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Advenchen Laboratories LLC, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Aldeyra Therapeutics Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Apexian Pharmaceuticals Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Ascentage Pharma Group International, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by AstraZeneca Plc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by BeiGene Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Bristol-Myers Squibb Co, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Calithera Biosciences Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Eisai Co Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Epizyme Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Karyopharm Therapeutics Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Merck & Co Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Mirati Therapeutics Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Moleculin Biotech Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Novartis AG, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Oncomatryx Biopharma SL, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Open Therapeutics LLC, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Otsuka Pharmaceutical Co Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Pfizer Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Pharma Mar SA, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Plexxikon Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Sino Biopharmaceutical Ltd, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Sorrento Therapeutics Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Tango Therapeutics Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Vyriad Inc, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Dormant Projects, 2022

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.